Erythroleukemia, also known as red leukemia, is a type of acute myeloid leukemia, clinically known as acute myeloid leukemia type m6. Red leukemia is relatively rare in clinical practice, and the main treatment is chemotherapy and allogeneic hematopoietic stem cell transplantation therapy. Erythroleukemia is firstly improved with various ancillary tests and then risk stratification, which is clinically divided into three types: low risk group, intermediate risk group and high risk group. Generally speaking, the beginning treatment phase of erythroleukemia is called the induction remission treatment phase, and the commonly used chemotherapy regimens include da regimen, ia regimen, ma regimen, etc. Chemotherapeutic agents include erythromycin, desoxorubicin, mitoxantrone, and cytarabine. If the patient achieves complete remission, maintenance therapy with medium or high dose cytarabine is possible. Also, if a suitable bone marrow donor is available, allogeneic hematopoietic stem cell transplantation therapy is available.